Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222794 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT00222794 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 66 participants.
The verdict
NCT00222794, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study proposes to examine the effect of atomoxetine on quality of life and negative symptoms such as social withdrawal, lack of interest in things, lack of thought content, flat emotions, slowed body movements and lack of drive and motivation in patients with schizophrenia or schizoaffective disorder. This study also examines the safety of using atomoxetine along with the conventional antipsychotic in these patients.
Interventions
- DRUG Atomoxetine (Strattera)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222794
The ClinicalTrials.gov registry entry for NCT00222794 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine (Strattera) is the first listed.
NCT00222794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222794 about?
NCT00222794 is a clinical study titled "A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia". This study proposes to examine the effect of atomoxetine on quality of life and negative symptoms such as social withdrawal, lack of interest in things, lack of thought content, flat emotions, slowed body movements and lack of drive and motivation in patients with schizophrenia or schizoaffective di...
What is the current status of trial NCT00222794?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2003-11. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00222794?
The interventions under investigation include: Atomoxetine (Strattera) (DRUG).
Who is sponsoring clinical trial NCT00222794?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.